|LRIG1 regulates cadherin-dependent contact inhibition directing epithelial homeostasis and pre-invasive squamous cell carcinoma development.|
|Jump to Full Text|
|PMID: 23208928 Owner: NLM Status: MEDLINE|
|Epidermal growth factor receptor (EGFR) pathway activation is a frequent event in human carcinomas. Mutations in EGFR itself are, however, rare, and the mechanisms regulating EGFR activation remain elusive. Leucine-rich immunoglobulin repeats-1 (LRIG1), an inhibitor of EGFR activity, is one of four genes identified that predict patient survival across solid tumour types including breast, lung, melanoma, glioma, and bladder. We show that deletion of Lrig1 is sufficient to promote murine airway hyperplasia through loss of contact inhibition and that re-expression of LRIG1 in human lung cancer cells inhibits tumourigenesis. LRIG1 regulation of contact inhibition occurs via ternary complex formation with EGFR and E-cadherin with downstream modulation of EGFR activity. We find that LRIG1 LOH is frequent across cancers and its loss is an early event in the development of human squamous carcinomas. Our findings imply that the early stages of squamous carcinoma development are driven by a change in amplitude of EGFR signalling governed by the loss of contact inhibition.|
|Liwen Lu; Vitor H Teixeira; ZhengQiang Yuan; Trevor A Graham; David Endesfelder; Krishna Kolluri; Noura Al-Juffali; Nicholas Hamilton; Andrew G Nicholson; Mary Falzon; Maik Kschischo; Charles Swanton; Nicholas A Wright; Bernadette Carroll; Fiona M Watt; Jeremy P George; Kim B Jensen; Adam Giangreco; Sam M Janes|
Related Documents :
|9673558 - Expression of cd44 variant 6 and lymphatic invasion: importance to lymph node metastasi...
1593688 - Lower incidence of unsuspected lymph node metastases in 521 consecutive patients with c...
1087608 - Experimental allergic encephalomyelitis.-- the effect of dexamethasone on growth and pr...
7857628 - Recurrent cervical lymphadenopathy: differential diagnosis with color-duplex sonography.
1453268 - Inhibin (10.7 kd prostatic peptide) in normal, hyperplastic, and malignant human endome...
23295308 - Prediction of the risk of harboring prostate cancer by a prebiopsy nomogram based on ex...
|Type: Journal Article; Research Support, Non-U.S. Gov't|
|Title: The Journal of pathology Volume: 229 ISSN: 1096-9896 ISO Abbreviation: J. Pathol. Publication Date: 2013 Mar|
|Created Date: 2013-02-15 Completed Date: 2013-04-23 Revised Date: 2014-08-12|
Medline Journal Info:
|Nlm Unique ID: 0204634 Medline TA: J Pathol Country: England|
|Languages: eng Pagination: 608-20 Citation Subset: IM|
|Copyright © 2012 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.|
|APA/MLA Format Download EndNote Download BibTex|
Cadherins / genetics, metabolism*
Carcinoma, Squamous Cell / genetics*, metabolism, pathology
Cell Line, Tumor
Cell Transformation, Neoplastic
Gene Expression Regulation, Neoplastic
Loss of Heterozygosity
Lung Neoplasms / genetics*, metabolism, pathology
Membrane Glycoproteins / genetics*, metabolism
Mice, Inbred C57BL
Mice, Inbred NOD
Nerve Tissue Proteins / genetics*, metabolism
Precancerous Conditions / genetics*, metabolism, pathology
Receptor, Epidermal Growth Factor / antagonists & inhibitors, genetics, metabolism
|079249//Wellcome Trust; 091730//Wellcome Trust; 14895//Cancer Research UK; 260290//European Research Council; //Department of Health; //Wellcome Trust|
|0/Cadherins; 0/LRIG1 protein, human; 0/Lrig1 protein, mouse; 0/Membrane Glycoproteins; 0/Multiprotein Complexes; 0/Nerve Tissue Proteins; EC 188.8.131.52/EGFR protein, mouse; EC 184.108.40.206/Receptor, Epidermal Growth Factor|
Journal ID (nlm-ta): J Pathol
Journal ID (iso-abbrev): J. Pathol
Journal ID (publisher-id): path
Publisher: John Wiley & Sons, Ltd, Chichester, UK
Copyright © 2013 Pathological Society of Great Britain and Ireland
Received Day: 12 Month: 6 Year: 2012
Revision Received Day: 18 Month: 10 Year: 2012
Accepted Day: 08 Month: 11 Year: 2012
Print publication date: Month: 3 Year: 2013
Electronic publication date: Day: 15 Month: 2 Year: 2013
Volume: 229 Issue: 4
First Page: 608 Last Page: 620
PubMed Id: 23208928
|LRIG1 regulates cadherin-dependent contact inhibition directing epithelial homeostasis and pre-invasive squamous cell carcinoma development|
|Vitor H Teixeira1†|
|Trevor A Graham34|
|Andrew G Nicholson7|
|Nicholas A Wright39|
|Fiona M Watt10|
|Jeremy P George1|
|Kim B Jensen11|
|Sam M Janes1*|
1Lungs for Living Research Centre, UCL Respiratory, University College London5 University Street, London, WC1E 6JF, UK
2MICU, The People’s Hospital of Guangxi530021, China
3Histopathology Laboratory, Cancer Research UK London Research Institute44 Lincoln’s Inn Fields, London, WC2A 3PX, UK
4Centre for Evolution and Cancer, UCSF Helen Diller Family Comprehensive Cancer CenterSan Francisco, CA, 94143-0875, USA
5University of Applied SciencesSüdallee 2, 53424, Remagen, Germany
6Cancer Research UK London Research InstituteLondon, WC2A 3LY, UK
7Department of Histopathology, Royal Brompton and Harefield NHS Foundation Trust, and National Heart and Lung Institute, Imperial CollegeLondon, UK
8Department of Histopathology, University College Hospital LondonLondon, UK
9Centre for Digestive Diseases, Barts and the London School of Medicine and Dentistry, Queen Mary University of LondonLondon, E1 2AD, UK
10Epithelial Cell Biology Laboratory, Cancer Research UK Cambridge Research InstituteRobinson Way, Cambridge, UK
11Wellcome Trust – Medical Research Council Stem Cell Institute, Department of Oncology, University of CambridgeTennis Court Road, CB2 LQR, Cambridge, UK
|Correspondence: *Correspondence to: Sam M Janes, Lungs for Living Research Centre, UCLRespiratory, University College London, 5 University Street, London, WC1E 6JF, UK. firstname.lastname@example.org
†These authors contributed equally to this study.
Dysregulation of EGFR signalling is a common feature of various lung diseases such as asthma, lung fibrosis, and lung cancer 1,2. EGFR signalling is also crucial for lung development as Egfr-null mice have defects in both branching and differentiation, whilst segregation of EGFR and its ligands regulates repair 3–5.
The EGFR family is a group of four structurally similar tyrosine kinases (EGFR, HER2/neu, ErbB-3, and ErbB-4) that dimerize upon ligand binding. EGFR is an important lung oncogene and is overexpressed in virtually all squamous carcinomas. Intriguingly, overexpression of EGFR is one of the earliest abnormalities in the bronchial epithelium of smokers and is present in all stages of pre-invasive squamous cell carcinoma including basal cell hyperplasia, squamous metaplasia, dysplasia, and carcinoma in situ6. We hypothesize that tissue homeostasis is maintained via strong endogenous regulation of EGFR signalling and that loss of this regulation leads to early-stage tumourigenesis.
Leucine-rich repeats and immunoglobulin like-domains (LRIG1) is one such inhibitor and in the epidermis it has been found to maintain epidermal stem cells in a non-proliferative state via negative regulation of EGFR signalling 7,8, with its loss being observed in psoriatic lesions and epidermal squamous cell carcinomas 9,10. There is, in fact, strong bioinformatic evidence of LRIG1’s role in tumourigenesis, with a recent study showing that LRIG1 was one of only four mis-expressed genes that relate to patient survival across epithelial cancer types 11. The mechanism for this is unknown.
In the following experiments, we show that LRIG1 is expressed in the epithelium of the upper murine airways. Loss of Lrig1 in murine airways leads to epithelial hyperproliferation, which is recapitulated with in vitro organotypic cultures where Lrig1-deficient cells fail to undergo cell–cell contact inhibition. We demonstrate that LRIG1 forms a ternary complex between LRIG1, E-cadherin, and EGFR, which upon cell–cell contact negatively regulates EGFR signalling. In human lung cancer cell lines, we show that re-expression of LRIG1 reduces cell growth and inhibits tumourigenesis in vivo. LRIG1 LOH occurs across many tumour types and particularly in squamous cell carcinomas. Finally, we demonstrate that LRIG1 may be an important trigger of carcinogenesis at the pre-invasive carcinoma stage by showing that LRIG1 loss is an early and consistent event in the pathogenesis of pre-invasive lung cancer lesions.
Adult, 2- to 4-month-old mice were used for experiments, housed in individually ventilated cages on a 12 h light/dark cycle, and allowed access to food and water ad libitum. Lrig1-null mice were a kind gift from Sathoshi Itami 9. All transgenic mice were maintained on a mixed background of 129, C57/Bl6, and CD1 inbred strains. Homozygote-deleted Lrig1 mice were compared with sex-matched littermate heterozygote Lrig1 mice as controls. Of note, heterozygote littermates were compared with wild-type littermates and found to have no difference in airway epithelial morphology, cellularity or proliferation (Supplementary Figure 1). Hence the breeding programme consisted of breeding a heterozygote with a knockout to maximize experimental mice numbers and subsequent experiments compared heterozygote littermates with knockouts. For experiments involving tracheal repair, mice were anaesthetized with isofluorane and tracheas damaged via oropharyngeal instillation of 15 µl of 2% polidocanol (a detergent agent that removes the airway epithelium, leaving an intact basement membrane) (Sigma, Dorset, UK) 12. BrdU was injected intraperitoneally (Zymed 00–0103; 100 µl concentrated reagent per 10 g body weight, intraperitoneally, 2 h pre-sacrifice). Tracheal samples were fixed in 4% paraformaldehyde and paraffin-embedded or snap-frozen in OCT. Mice were sacrificed by sodium pentobarbitol overdose and sentinel screenings for common murine pathogens were used throughout the course of these studies. All in vivo experiments involved a minimum sample size of five animals per group, were repeated at least twice, and were performed under the terms of a UK Home Office project licence.
Human and murine tissue sections were fixed in 10% neutral buffered formalin or 4% paraformaldehyde, processed, and sectioned at 4 µm thickness. Human biopsy samples were obtained via fibre optic bronchoscopy, with patient consent under institutional ethical approval. Human and murine haematoxylin and eosin (H&E) staining was performed using an automated staining system (TissueTek). All human biopsy specimens were subjected to routine histopathological diagnosis by two consultant lung histopathologists (MF and AN). Air–liquid interface (ALI) culture whole-mounts were fixed overnight in 4% paraformaldehyde prior to antibody immunostaining.
Immunofluorescent or immunohistochemical human and murine tissue section and/or ALI whole-mount antibody staining followed standard conditions 13. Species-appropriate secondary antibodies included streptavidin-HRP (DAKO, Cambridgeshire, UK) (Ki67) or directly conjugated Alexafluor dyes (all other primary antibodies). For immunofluorescence or immunohistochemistry, we used the following antibodies: LRIG1 (S Itami, University of Osaka, Japan), LRIG1 (rabbit; Abcam, Cambridge, MA, USA), K14 (rabbit; Covance, Leeds, UK), K14 (LL002) (mouse IgG3; F Watt, CRUK, Cambridge), CCSP (goat; gift from B Stripp, Duke University, USA) 14, acetylated tubulin (mouse; Sigma), Ki67 (rabbit; Sigma), BrdU (ICR1) (mouse; AbD Serotec, Kidlington, UK), CDH1 (rat; Sigma), CDH1 (mouse; Watt, CRUK, UK), flag1 (mouse; Sigma), and EGFR1 (mouse; Abcam). Secondary antibodies were conjugated to HRP, Alexa555, Alexa633 or Alexa488 (Invitrogen, Paisley, UK). Images were acquired using a Leica TCS Tandem or SPE confocal or an Olympus bright-field microscope. Confocal images were imported into Volocity software (Perkin Elmer, Bucks, UK) for accurate measurement of intensity. Four representative z-stack images acquired with a 40× objective were analysed for each of three animals in Lrig-null and Het groups. All images were post-processed using Adobe Photoshop (Photomerge, rotate, crop, brightness, and contrast adjustments).
Epithelial height and cell density were determined using Volocity image analysis software. We quantified the abundance of specific tracheal cell phenotypes as a function of epithelial basement membrane length 15. Two-tailed unpaired t-tests were performed to assess the significance of differences between epithelial heights and signal intensity between two groups and the Mann–Whitney U-test was used for cell phenotype and proliferation. One-way ANOVA and Tukey’s multiple comparison test were performed to assess the signal intensity from fluorescent images between three groups. Statistical significance was accepted at p < 0.05 for all analyses, and error bars represent the standard error of the mean. All statistical analyses were performed using GraphPad Prism and Microsoft Excel.
A549 and H357 cells were transduced with pBabePuro-Lrig1Flag and pBabe Puro 8. A549 cells were grown in DMEM + 10% FBS + L-glutamine. Transduction of cancer cells was carried out as previously described 16. Briefly, ecotropic Phoenix packaging cells were transiently transfected with retroviral vectors, and virus-containing supernatants were used to infect AM12 packaging cells, as described previously 17. Stably transduced AM12 cells were cultured with 2.5 µg/ml puromycin. Cancer cells were transduced with retroviral vectors either by co-culture with AM12 cells 18 or by incubation with AM12 supernatant 17. All cells were obtained from Cancer Research UK, London Research Institute (CRUK, London, UK) and were authenticated by the integrin expression profile (H357) and SpC expression (A549) 19.
Mouse tracheal epithelial cells (MTECs) were harvested using aseptic techniques, pooled, cleaned, and digested in pronase as previously described 20. Enzyme isolated cells were counted and seeded in 12-well Transwell dishes (Sigma) at 2 × 105 cells per well in MTEC/plus. Upon visually reaching confluence (usually day 9 post-plating), the media was changed to MTEC/basic plus retinoic acid to enhance differentiation at an air–liquid interface (ALI) 20. Cells were harvested at indicated time points and subjected to immunostaining and immunoblotting. BrdU was added 3 h before cell fixation (ZYMED 00–0103: in vivo 100 µl concentrated reagent per 10 g body weight, intraperitoneal, 2 h pre-sacrifice; in vitro exp 1 : 100). In some experiments, cells were incubated overnight with MTEC/basic medium with no growth factors.
Eight-week-old male, NOD/SCID IL2 Rγ knockout mice were used for tumourigenesis experiments. All mouse studies were performed in accordance with British Home Office procedural and ethical guidelines. Animals were housed in pathogen-free conditions with filtered air, and autoclaved food and water were available ad libitum. H357 empty vector and LRIG1 transduced cells were injected in a suspension of two million cells in a total of 200 µl, subcutaneously in the right flank with a 29 G needle. Tumours were measured every 2–5 days with callipers, and the volume was calculated as (4/3)πr3, where r is the estimated radius 21.
Cells were scraped from in vitro cultures into RIPA buffer supplemented by complete protease inhibitors (Roche, West Sussex, UK) and phosSTOP phosphatase inhibitor (PhosphoSafe™ Extraction Reagent Novagen). Equal amounts of protein were loaded and immunoblotted using the antibodies indicated. Lysates for immunoprecipitation were prepared by scraping cells into NP40 buffer [20 mM Tris–HCl (pH 8), 137 mM NaCl, 10% glycerol, 1% Nonidet P-40 (NP-40), 2 mM EDTA, supplemented by complete protease inhibitor] at 4°C on an agitator for 30 min. For immunoblotting and immunoprecipitation, we used the following antibodies: phospho-EGFR1 (rabbit; Invitrogen), EGFR (rabbit 1005; Santa Cruz Biotechnology, Santa Cruz, CA, USA), phospho-ERK1/2 (rabbit; Cell Signaling, Beverley, MA, USA), ERK2 (goat; Santa Cruz Biotechnology), flag1 (mouse; Sigma), CDH1 (mouse; Watt, CRUK, UK), phospho-Akt (mouse; Cell Signaling), and β-actin (mouse; Sigma).
RNA was extracted from cultured or freshly isolated MTECs and human A549, H357 and BEAS-2b cells using a commercially available SV RNA isolation kit (Promega, Madison, WI, USA). Carcinoma in situ (CIS) lesions and a normal area of epithelium biopsied at the same bronchoscopy were laser microdissected from formalin-fixed, paraffin-embedded (FFPE) tissues from ten patients. Briefly, multiple sections of each sample were cut, with the first and last in a series stained with H&E for inspection by two lung pathologists. After confirming the diagnosis and dewax/staining the samples using the Arcturus® Paradise® PLUS Reagent System (Applied Biosystems, Foster City, CA, USA), we laser capture microdissected the samples using the Zeiss Palm Microbeam system (Carl Zeiss, Cambridge, UK and Quanta Biosciences, Leicestershire, UK). RNA was extracted from both microdissected CIS and normal lung epithelium FFPE tissues using the RNeasy FFPE kit (Qiagen, Valencia, CA, USA). RNA concentration was measured using the Qubit® 2.0 Fluorometer (Invitrogen, Carlsbad, CA, USA). RNA integrity was analysed using the Agilent 2100 Bioanalyzer (Agilent, Santa Clara, CA, USA). Reverse transcription (RT) was performed with qScript™ cDNA SuperMix (Quanta Biosciences) according to the manufacturer’s protocol. Real-time quantitative RT-PCR analysis was executed on an Eppendorf real-time PCR machine, using TaqMan gene expression assay probes (Applied Biosystems) for LRIG1 (Hs01006148_m1) and EGFR (Hs01076073_m1) and TaqMan endogenous control probes (Applied Biosystems) for 18s rRNA (Hs03928990_g1), β2-M (Hs00187842_m1), and HPRT (Hs01003267_m1). As the size of most RNA fragments from typical FFPE samples is around 100 nucleotides, all the TaqMan gene expression assay and endogenous probes were chosen to produce amplicons as short as possible (lower than 73 nt). Expression of the LRIG1 and EGFR mRNA was quantified using the threshold cycle (Ct) method and normalized to the amount of 18S rRNA, HPRT, and β2-M. The mean of several Cts of the housekeeping genes had to be lower than 30, otherwise the sample was treated as unsuitable for qRT-PCR. Each sample was tested in triplicate and a sample without template was included in each run as a negative control.
AffymetrixSNP 6.0 data were provided by the Wellcome Trust Sanger Institute Cancer Genome Project. The PICNIC algorithm uses a hidden Markov model approach to estimate allele-specific integer copy numbers 23. We defined all genomic regions with no copy of at least one LRIG1 allele as LRIG1 LOH. Genomic regions showing zero copies of the minor allele and two or more copies of the major allele were defined as copy neutral LOH. The percentage of cell lines showing no LOH, copy neutral LOH, and hemizygous deletions was counted for (i) all lung cancer cell lines and (ii) all squamous cell lines. The data were obtained from the Wellcome Trust Sanger Institute Cancer Genome Project website, http://www.sanger.ac.uk/genetics/CGP.
DNA was extracted from ten microdissected CIS and ten matched normal lung epithelium FFPE tissues using the Arcturus® PicoPure® DNA Extraction Kit (ABI). LOH was analysed by PCR amplification using one informative LRIG1 microsatellite marker (66457092–66457543). The fluorescent-labelled primer sequences for the microsatellite marker were (6FAM)-5′-TCTTTAAGAAGACTCCCTGTTTGTT-3′ and 5′-GCCCCCTGCTGTCAAACT-3′. PCR reactions were run on an ABI 373 DNA sequencer, with real-time fluorescence detection of PCR products. An internal size standard was used in each lane to give accurate base-pair determinations. Data were inspected using the Peak Scanner software (ABI).
Allele ratios were determined by measuring the fluorescence intensity (peak height) of the smaller (base-pair) allele 1 relative to the FU intensity of the larger allele 2 (A/B). LOH was determined by assessing the ratio of peak heights in CIS tissue samples relative to the ratio in the corresponding normal samples; a two-fold or greater change in the allelic ratio was considered evidence of LOH.
Using immunofluorescence and in situ hybridization, we showed that normal murine airways express LRIG1 throughout the trachea and first few bronchial divisions (Figures 1a and 1b, day 0/undamaged, and Supplementary Figure 2). LRIG1 is expressed ubiquitously in the airways during steady-state homeostasis with co-immunofluorescence staining seen with keratin 14-positive cells (basal), Clara-cell secretory protein-positive cells (Clara cells), and acetylated tubulin-positive cells (ciliated) (data not shown).
As EGFR signalling is known to be important during tissue repair, we first analysed whether Lrig1 expression changes upon airway epithelial damage after oropharyngeal instillation of the detergent polidocanol. By indirect immunofluorescence and in situ hybridization, we observed a transient reduction in LRIG1 expression 48 h post-injury (Figures 1a and 1b and Supplementary Figure 2). This coincided with the onset of the proliferative phase of the injury response (Supplementary Figure 3).
In order to determine whether Lrig1 is required for airway homeostasis, we analysed tissue from the Lrig1 knockout mouse model 9. Loss of LRIG1 was confirmed by immunofluorescence (Supplementary Figure 4a) and caused a significant increase in epithelial thickness and the number of cells per 200 µm of basement membrane in the trachea and first two bronchial generations compared with littermate controls (mean ± SEM; 24.9 ± 1.2 mm versus 19.1 ± 1.7 mm; unpaired t-test p = 0.03; and 118.3 ± 8.9 versus 81.3 ± 3.0; unpaired t-test p = 0.001, Figures 1c–1f). Ki67 staining of the trachea and bronchi demonstrated that the increased thickness is associated with increased proliferation in the Lrig1−/− airway epithelium (8.6% ± 1.1% of Lrig1−/− versus 2.4% ± 0.3% of control cells express Ki67; Mann–Whitney; p = 0.03; Figure 1g). In spite of the significant changes to the epithelium, the proportion of basal, Clara, and ciliated cells was maintained upon loss of LRIG1 (Supplementary Figures 4b–4d). We conclude that LRIG1 controls proliferation within the upper airways without affecting lineage-specific differentiation.
In the epidermis, LRIG1 regulates EGFR signalling 8. Immunofluorescence staining for activated EGFR showed increased pEGFR levels in Lrig1 KO mice during steady-state homeostasis (Figures 1h, day 0, and 1i). Following injury by polidocanol, the levels of pEGFR increased in control animals in line with cellular proliferation (Supplementary Figure 3) and the difference between Lrig1 KO and control animals disappeared (Figures 1h, day 2, and 1j). In control animals, the levels of EGFR activation subsequently returned to normal by day 7, but remained elevated in the Lrig1−/− mice (Figures 1h, day 7, and 1k). This is associated with increased proliferation at day 7 in Lrig1−/− mice compared with littermate controls (32.7% ± 5.1% versus 21.1% ± 4.1%, Mann–Whitney p = 0.03) (Figure 1l). The dynamic expression pattern of LRIG1 during injury suggests that it controls either airway cell differentiation or proliferation. As Lrig1−/− mice display normal epithelial differentiation (Figure 1), this indicates that LRIG1 controls proliferation.
To further examine the hyperproliferative phenotype of the Lrig1−/− mouse airways, we used murine tracheal epithelial cell (MTEC) air–liquid interface (ALI) cultures 24. In ALI cultures, the initial proliferative phase of the culture was carried out submerged in media until day 9, followed by a differentiation phase of confluent cells at an ALI (Figure 2a). Proliferation in sub-confluent MTEC cultures was examined at day 7 in submerged cultures or after moving to ALI at day 14 by incubating with BrdU 3 h before harvest. Day 7 pre-confluent cultures showed equivalent cellular proliferation in Lrig1−/− and control MTECs (Figure 2b). In contrast, proliferation of Lrig1−/− MTECs post-confluence (day 14) was significantly increased compared with littermate controls (Figure 2c). Cell fate decisions of confluent ALI Lrig1−/− cultures were again normal, with equivalent levels of K14 and acetylated tubulin-expressing cells (Figures 2d and 2e). Protein analysis from Lrig1−/− and control MTEC cultures demonstrated increased activation of the EGFR pathway under conditions with and without the EGF ligand (Figure 2f). Thus, LRIG1 regulates proliferation and EGFR responsiveness in MTEC cultures.
The loss of contact inhibition in the Lrig1−/− airway epithelial cells suggests that LRIG1 may be a tumour suppressor in lung cancer cells. Human lung A549 (adenocarcinoma) and H357 (squamous) cancer cell lines show little or no expression of LRIG1 compared with normal human bronchial epithelial cells (BEAS-2B), while having high expression of EGFR (Figure 3a). These cell lines were transduced with a retrovirus expression vector encoding a flag-tagged LRIG1 construct or empty vector control (transduction confirmed by immunofluorescence, immunoblotting, and qPCR, Figures 3b and 3c) and effects on proliferation were examined pre- and post-confluence. At pre-confluence, overexpression of LRIG1 did not affect proliferation (A549: 78.2% ± 3.8% versus 74.9% ± 4.4%, p > 0.05; H357: 58.0% ± 6.6% versus 56.1% ± 3.9%, p > 0.05) (Figures 3d and 3f). However, upon confluence, expression of exogenous Lrig1 caused a significant reduction in proliferation (A549s: 13.3% ± 0.7% versus 6.1% ± 1.7%, p = 0.03; H357: 56.3% ± 7.7% versus 40.1% ± 6.9%, p = 0.03) (Figures 3e and 3g). Hence, the re-expression of LRIG1 is sufficient to restore cell–cell contact inhibition. Moreover, this is specific to cancerous cells lines, as normal bronchial epithelial cells (BEAS-2B cells) that express endogenous LRIG1 show no change in cell proliferation upon expression of exogenous LRIG1 (Supplementary Figure 5).
To examine LRIG1 effects on tumourigenicity, we retrovirally transduced the LRIG1-negative human squamous carcinoma cell line H357 with LRIG1 or empty vector control and cells were injected subcutaneously into immunocompromised mice. In the empty vector group, nine of ten tumours grew over 7 weeks, while only one of 11 grew in the LRIG1 transduced cells (Figures 3h–3j).
In order to understand how LRIG1 affects proliferation upon cell–cell contact, we first examined the activation of the EGFR signalling pathways in LRIG1-null cells compared with LRIG1 transduced cells. We found that introduction of LRIG1 to human cancer cells reduced phospho-EGFR levels and the downstream effecter phospho-ERK1/2, while having no effect on the activation of Akt (Figure 4a). Homophilic E-cadherin interactions are known to affect EGFR signalling in a similar manner 25, and we hypothesized that LRIG1 controls EGFR activity via functional adherens junctions. While LRIG1 transduction did not alter E-cadherin levels (Figures 4b and 4c), we did, however, observe that EGFR and E-cadherin, as well as EGFR and LRIG1, co-localized at cell–cell contacts in a calcium-dependent manner (Figures 4d–4f). Co-immunoprecipitation experiments showed a modest interaction between E-cadherin and EGFR in the absence of LRIG1. This interaction was greatly enhanced upon LRIG1 transduction, showing that the three molecules form a ternary complex upon confluence (Figures 4g and 4h). We conclude that in both murine tracheal epithelial cells and human lung cancer cells, LRIG1 is required for effective density-dependent growth inhibition through inhibition of the EGFR–ERK1/2 pathway and that it forms a ternary complex at the cell membrane with E-cadherin and EGFR upon cell–cell contact.
As loss of LRIG1 causes hyperproliferation in vivo and failure of contact inhibition in vitro, we hypothesized that LRIG1 loss is an early initiation step for the development of cancers in the airways. This will lead to the formation of hyperplastic lesions and an environment prone to accumulation of additional genetic abnormalities 26.
mRNA and protein analysis of ten matched samples, comparing a pre-invasive carcinoma in situ (CIS) lesion with a normal airway biopsy taken from the same individual at the same time, showed reduced gene expression and immunoreactivity for LRIG1 in pre-invasive tissue compared with normal epithelium in all ten patients (Figures 5a and 5b). The reduction in LRIG1 expression was functionally mirrored by increased EGFR signalling (Figures 5c and 5d). This strongly identifies loss of LRIG1 as an early event in the pathogenesis of squamous cell lung cancer.
Several studies have shown that loss of LRIG1 occurs in cancer and is associated with a poor prognosis 10,11,27-29. We performed loss of heterozygosity (LOH) analysis at the LRIG1 locus in 138 lung cancer and 37 squamous cell carcinoma cell lines as part of the Sanger Cancer Genome Project, which was carried out using the Affymetrix SNP6.0 array in conjunction with a bespoke algorithm (PICNIC: Predicting Integral Copy Numbers In Cancer) 23. This analysis showed that LOH at the LRIG1 locus had occurred in 75% of the lung cancer cell lines. Fifty-seven per cent of the cell lines showed copy neutral LOH and 18% showed hemizygous deletion (Figure 5e). Furthermore, 76% of the squamous cell carcinoma cell lines including those from the cervix, lung, head and neck, oesophagus, skin, tongue, upper aerodigestive tract, upper respiratory tract, and vulva had LOH of LRIG1 (Figure 5f). In all but one case, LOH was due to whole-arm loss or large chromosomal alteration on the 3p region, and so was not specifically targeted to the LRIG1 locus, but all do overlap with the LRIG1 locus (Supplementary Figures 6a and 6b).
Intriguingly, LOH also occurred in pre-invasive lung cancer lesions. Microsatellite LOH analysis was performed on the same ten pre-invasive lung cancer lesions and their patient matched controls using a heterozygous microsatellite marker within the LRIG1 gene, and revealed LRIG1 LOH in four pre-invasive lung cancer samples (Figures 5g and 5h). The lack of frozen tissue from these samples meant that we were unable to examine promoter methylation or seek a gene mutation in the remaining allele.
Our data identify LRIG1 as an important regulator of tissue homeostasis in the major airways. We have demonstrated that LRIG1 acts as a tumour suppressor and forms a ternary complex at adherens junctions with E-cadherin and EGFR. LRIG1 controls EGFR/ERK1/2 activation upon cell–cell contact. Pre-invasive lung cancer lesions are characterized by loss of contact inhibition, increased epithelial proliferation, and elevated EGFR activation 6. Our findings therefore identify loss of LRIG1 as an early event in the pathogenesis of squamous cell lung carcinomas and provide insight into elevated EGFR activation in pre-invasive lesions. As loss of LRIG1 has been identified as one of four key events that predict patient outcome across five tumour types including 129 lung squamous cell carcinoma patients 11, we propose that this may be a general mechanism for controlling homeostasis in other epithelial tissues such as the epidermis 7. This has widespread implications for the role of cell–cell contact inhibition and regulation of EGFR signalling in development, tissue homeostasis, and disease.
EGFR and E-cadherin are known to co-localize on cell–cell contact, as we too have demonstrated. While E-cadherin protein levels increase five times at cell confluence, EGFR mRNA and protein levels remain constant but tyrosine kinase activity is reduced 30. The mechanism by which EGFR activation is reduced at cell confluence was not previously understood. A postulated way of producing this fall in EGFR phosphorylation is a direct inhibitory interaction between E-cadherin and EGFR but to our knowledge there are no data to support this. Our data show, however, that the endogenous EGFR inhibitory molecule LRIG1 is also recruited to the complex at cell confluency and is required for density-dependent growth inhibition.
LRIG1 is expressed in all tissues 31, and endogenous and synthetic LRIG1 has been confirmed to be plasma membrane-bound by cell surface biotinylation/precipitation and confocal immunofluorescence and laser microscopy 19. Previous data suggest that LRIG1 blocks EGFR activation through two possible mechanisms. First, LRIG1 transcript and protein are known to be up-regulated after EGF stimulation, which is thought to be a negative feedback mechanism, whereby it associates with all four EGFR analogues and both proteins are subsequently ubiquitinated by ubiquitin ligases 32. Alternatively, LRIG1 has been postulated to bind EGFR in a monomeric ‘attenuated’ state. This is because LRIG1 with the intracellular domain, including c-Cbl E3 ubiquitin ligase binding domain deleted, still attenuates EGFR activity without physical down-regulation of the protein and without competing for EGF binding 33. Our data suggest that the latter may be the case in density-dependent growth inhibition as we see no down-regulation of the EGFR protein itself but a dramatic fall in EGFR activity at cell–cell contact with LRIG1 expression.
In our extremely rare human samples of pre-invasive cancer lesions that have a matched local biopsy of normal airways, we have demonstrated loss of LRIG1 expression and LOH in four of ten lesions, but none in normal biopsies. It is tempting to hypothesize that this goes some way to understanding the mechanism of LRIG1 loss in the airways of smokers but our samples had DNA that was too degraded to examine for methylation or mutation abnormalities in the remaining allele. Our murine data demonstrating a clear phenotypic difference between Lrig1-null mice and heterozygotes mean that the LOH that we see in humans is unlikely to result in haploinsufficiency as a cause for the human pre-invasive lesions.
In addition to being unable to definitively define the genetic cause for loss of LRIG1 expression in the human pre-invasive lung cancer lesions, a further weakness in our study is the lack of definitive proof that the ternary complex formation leads to cell–cell contact inhibition. We have shown that LRIG1 is required and that LRIG1 forms a ternary complex with EGFR and E-cadherin but have not definitively demonstrated that the complex is necessary. To study this further, it would be interesting to make a series of E-cadherin mutants to try to inhibit LRIG1 binding in a bid to block cell–cell contact inhibition in the presence of LRIG1.
In summary, we have established LRIG1 as an important tumour suppressor gene in lung cancer in vitro and in vivo, with its loss occurring in the pre-invasive stages of human squamous carcinoma development. LRIG1 loss appears to be among the earliest abnormalities occurring in pre-cancerous airway epithelium, possibly leading to abnormal areas of proliferative epithelium that attract subsequent genetic mutations. Examination of data from expression profiling of CIS lesions confirms LRIG1 loss in CIS with a six-fold fall compared with normal epithelium 34. Whether this phenotype can be reversed may have an important impact on future chemopreventative strategies.
We would like to thank Richard Poulsom and Rosemary Jeffery at the Histopathology Laboratory at CR-UK London Research Institute for their technical expertise and help with in situ hybridization. We thank Steve Bottoms for tissue processing and embedding, and members of the UCL Centre for Respiratory Research for helpful comments and critical evaluation of the manuscript. We thank Chris Boshoff and Daniel Hochhauser for their help with the manuscript. SJ is a Wellcome Trust Senior Fellow in Clinical Science and is supported by the Rosetrees Trust. AG is a recipient of a European Research Council Starting Investigator award. KJ is a Wellcome Trust Career Development Fellow. Laser capture microdissection was performed in the UCL Cancer Institute and supported by the Experimental Cancer Medicine Centre. This work was partially undertaken at UCLH/UCL, which received a proportion of funding from the Department of Health’s NIHR Biomedical Research Centre’s funding scheme (SJ). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
LL, VHT, TAG, KBJ, AG, and SMJ conceived and designed the experiments. LL, VHT, ZY, DE, KK, NA, and NJH performed the experiments. LL, VHT, TAG, DE, KBJ, AG, and SMJ analysed the data. AN, MF, MK, CS, NAW, BC, FMW, JG, KBJ, AG, and SMJ contributed reagents/materials/analysis tools. VHT, AG, and SJ wrote the paper.
|1.||Puddicombe SM,Polosa R,Richter A,et al. Involvement of the epidermal growth factor receptor in epithelial repair in asthmaFASEB JYear: 2000141362137410877829|
|2.||Tyner JW,Kim EY,Ide K,et al. Blocking airway mucous cell metaplasia by inhibiting EGFR antiapoptosis and IL-13 transdifferentiation signalsJ Clin InvestYear: 200611630932116453019|
|3.||Kim S,Schein AJ,Nadel JA. E-cadherin promotes EGFR-mediated cell differentiation and MUC5AC mucin expression in cultured human airway epithelial cellsAm J Physiol Lung Cell Mol PhysiolYear: 2005289L1049L106016055478|
|4.||Miettinen PJ,Warburton D,Bu D,et al. Impaired lung branching morphogenesis in the absence of functional EGF receptorDev BiolYear: 19971862242369205141|
|5.||Vermeer PD,Einwalter LA,Moninger TO,et al. Segregation of receptor and ligand regulates activation of epithelial growth factor receptorNatureYear: 200342232232612646923|
|6.||Rusch V,Klimstra D,Linkov I,et al. Aberrant expression of p53 or the epidermal growth factor receptor is frequent in early bronchial neoplasia and coexpression precedes squamous cell carcinoma developmentCancer ResYear: 199555136513727882337|
|7.||Jensen KB,Collins CA,Nascimento E,et al. Lrig1 expression defines a distinct multipotent stem cell population in mammalian epidermisCell Stem CellYear: 2009442743919427292|
|8.||Jensen KB,Watt FM. Single-cell expression profiling of human epidermal stem and transit-amplifying cells: Lrig1 is a regulator of stem cell quiescenceProc Natl Acad Sci U S AYear: 2006103119581196316877544|
|9.||Suzuki Y,Miura H,Tanemura A,et al. Targeted disruption of LIG-1 gene results in psoriasiform epidermal hyperplasiaFEBS LettYear: 2002521677112067728|
|10.||Tanemura A,Nagasawa T,Inui S,et al. LRIG-1 provides a novel prognostic predictor in squamous cell carcinoma of the skin: immunohistochemical analysis for 38 casesDermatol SurgYear: 20053142343015871317|
|11.||Rouam S,Moreau T,Broet P. Identifying common prognostic factors in genomic cancer studies: a novel index for censored outcomesBMC BioinformaticsYear: 20101115020334636|
|12.||Macpherson H,Keir P,Webb S,et al. Bone marrow-derived SP cells can contribute to the respiratory tract of mice in vivoJ Cell SciYear: 20051182441245015923657|
|13.||Giangreco A,Lu L,Mazzatti DJ,et al. Myd88 deficiency influences murine tracheal epithelial metaplasia and submucosal gland abundanceJ PatholYear: 201122419020221557220|
|14.||Reynolds SD,Zemke AC,Giangreco A,et al. Conditional stabilization of beta-catenin expands the pool of lung stem cellsStem CellsYear: 2008261337134618356571|
|15.||Giangreco A,Reynolds SD,Stripp BR. Terminal bronchioles harbor a unique airway stem cell population that localizes to the bronchoalveolar duct junctionAm J PatholYear: 200216117318212107102|
|16.||Janes SM,Ofstad TA,Campbell DH,et al. Transient activation of FOXN1 in keratinocytes induces a transcriptional programme that promotes terminal differentiation: contrasting roles of FOXN1 and AktJ Cell SciYear: 20041174157416815316080|
|17.||Legg J,Jensen UB,Broad S,et al. Role of melanoma chondroitin sulphate proteoglycan in patterning stem cells in human interfollicular epidermisDevelopmentYear: 20031306049606314573520|
|18.||Janes SM,Watt FM. Switch from alphavbeta5 to alphavbeta6 integrin expression protects squamous cell carcinomas from anoikisJ Cell BiolYear: 200416641943115289499|
|19.||Nilsson J,Starefeldt A,Henriksson R,et al. LRIG1 protein in human cells and tissuesCell Tissue ResYear: 2003312657112684867|
|20.||You Y,Richer EJ,Huang T,et al. Growth and differentiation of mouse tracheal epithelial cells: selection of a proliferative populationAm J Physiol Lung Cell Mol PhysiolYear: 2002283L1315L132112388377|
|21.||Loebinger MR,Giangreco A,Groot KR,et al. Squamous cell cancers contain a side population of stem-like cells that are made chemosensitive by ABC transporter blockadeBr J CancerYear: 20089838038718219291|
|22.||Poulsom R,Longcroft JM,Jeffery RE,et al. A robust method for isotopic riboprobe in situ hybridisation to localise mRNAs in routine pathology specimensEur J HistochemYear: 1998421211329728289|
|23.||Greenman CD,Bignell G,Butler A,et al. PICNIC: an algorithm to predict absolute allelic copy number variation with microarray cancer dataBiostatisticsYear: 20101116417519837654|
|24.||Giangreco A,Lu L,Mazzatti D,et al. Myd88 deficiency influences murine tracheal epithelial differentiation and submucosal gland abundanceJ PatholYear: 201122419020221557220|
|25.||Qian X,Karpova T,Sheppard AM,et al. E-cadherin-mediated adhesion inhibits ligand-dependent activation of diverse receptor tyrosine kinasesEMBO JYear: 2004231739174815057284|
|26.||Hanahan D,Weinberg RA. Hallmarks of cancer: the next generationCellYear: 201114464667421376230|
|27.||Jensen KB,Jones J,Watt FM. A stem cell gene expression profile of human squamous cell carcinomasCancer LettYear: 2008272233118657901|
|28.||Lindstrom AK,Ekman K,Stendahl U,et al. LRIG1 and squamous epithelial uterine cervical cancer: correlation to prognosis, other tumour markers, sex steroid hormones, and smokingInt J Gynecol CancerYear: 20081831231717624990|
|29.||Guo D,Nilsson J,Haapasalo H,et al. Perinuclear leucine-rich repeats and immunoglobulin-like domain proteins (LRIG1-3) as prognostic indicators in astrocytic tumoursActa NeuropatholYear: 200611123824616532360|
|30.||Takahashi K,Suzuki K. Density-dependent inhibition of growth involves prevention of EGF receptor activation by E-cadherin-mediated cell–cell adhesionExp Cell ResYear: 19962262142228660958|
|31.||Nilsson J,Vallbo C,Guo D,et al. Cloning, characterization, and expression of human LIG1Biochem Biophys Res CommunYear: 20012841155116111414704|
|32.||Gur G,Rubin C,Katz M,et al. LRIG1 restricts growth factor signalling by enhancing receptor ubiquitylation and degradationEMBO JYear: 2004233270328115282549|
|33.||Goldoni S,Iozzo RA,Kay P,et al. A soluble ectodomain of LRIG1 inhibits cancer cell growth by attenuating basal and ligand-dependent EGFR activityOncogeneYear: 20072636838116847455|
|34.||Lonergan KM,Chari R,Coe BP,et al. Transcriptome profiles of carcinoma-in-situ and invasive non-small cell lung cancer as revealed by SAGEPLoS OneYear: 20105e916220161782|
The following supporting information may be found in the online version of this article.Figure S1
No significant difference in airway epithelial morphology, cellularity or proliferation was found between LRIG1 WT and HET mice.
Click here for additional data file (path0229-0608-sd1.png)
Deletion of Lrig1 causes hyperproliferation of the upper airways.
Click here for additional data file (path0229-0608-sd2.png)
Demonstration of polidocanol damage to the upper airways.
Click here for additional data file (path0229-0608-sd3.png)
Lrig1 deletion does not affect cell fate decisions in vivo.
Click here for additional data file (path0229-0608-sd4.png)
LRIG1 transduction does not affect density-dependent growth inhibition in normal epithelial BEAS-2B cells with endogenous LRIG1 expression.
Click here for additional data file (path0229-0608-sd5.doc)
(a, b) Regions of allelic loss for each cancer cell line that showed LOH of the LRIG1 locus.
Click here for additional data file (path0229-0608-sd6.png)
Keywords: EGFR, LRIG1, squamous cell carcinoma, lung cancer, pre-invasive, E-cadherin, cell-cell contact.
Previous Document: Mapping and sequencing DNA using nanopores and nanodetectors.
Next Document: Investigation on chemotactic drug targeting (chemotaxis and adhesion) inducer effect of GnRH-III der...